Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

Abstract Background Empagliflozin (empa), a selective sodium–glucose cotransporter (SGLT)2 inhibitor, reduced cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk independent of glycemic control. The cardiovascular protective eff...

Full description

Bibliographic Details
Main Authors: Sin-Hee Park, Muhammad Akmal Farooq, Sébastien Gaertner, Christophe Bruckert, Abdul Wahid Qureshi, Hyun-Ho Lee, Djamel Benrahla, Brigitte Pollet, Dominique Stephan, Patrick Ohlmann, Jean-Marc Lessinger, Eric Mayoux, Cyril Auger, Olivier Morel, Valérie B. Schini-Kerth
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Cardiovascular Diabetology
Subjects:
Empagliflozin
SGLT2
Endothelial function
Heart function
Heart structure
Senescence
Online Access:http://link.springer.com/article/10.1186/s12933-020-00997-7

Internet

http://link.springer.com/article/10.1186/s12933-020-00997-7

Similar Items